These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 17551144)
21. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429 [TBL] [Abstract][Full Text] [Related]
23. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828 [TBL] [Abstract][Full Text] [Related]
24. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572 [TBL] [Abstract][Full Text] [Related]
25. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546 [TBL] [Abstract][Full Text] [Related]
26. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392 [TBL] [Abstract][Full Text] [Related]
27. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097 [TBL] [Abstract][Full Text] [Related]
28. Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Garrisi VM; Bongarzone I; Mangia A; Cremona M; De Bortoli M; Vaghi E; Galetta D; Pastorino U; Quaranta M; Abbate I; Paradiso A Clin Biochem; 2011 Jul; 44(10-11):936-40. PubMed ID: 21539823 [TBL] [Abstract][Full Text] [Related]
29. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Jänne PA; Johnson BE Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820 [TBL] [Abstract][Full Text] [Related]
30. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432 [TBL] [Abstract][Full Text] [Related]
31. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612 [TBL] [Abstract][Full Text] [Related]
32. Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer. Inomata M; Shukuya T; Takahashi T; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Murakami H; Harada H; Endo M; Yamamoto N Anticancer Res; 2011 Dec; 31(12):4519-23. PubMed ID: 22199325 [TBL] [Abstract][Full Text] [Related]
33. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Hirsch FR; Varella-Garcia M; Cappuzzo F Oncogene; 2009 Aug; 28 Suppl 1():S32-7. PubMed ID: 19680294 [TBL] [Abstract][Full Text] [Related]
34. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Faehling M; Eckert R; Kamp T; Kuom S; Griese U; Sträter J; Ott G; Spengler W Lung Cancer; 2013 Jun; 80(3):306-12. PubMed ID: 23489557 [TBL] [Abstract][Full Text] [Related]
35. Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib. Chen MJ; Zhong W; Zhang L; Zhao J; Li LY; Wang MZ Chin Med J (Engl); 2013 Jun; 126(12):2235-41. PubMed ID: 23786931 [TBL] [Abstract][Full Text] [Related]
36. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Yang JJ; Chen HJ; Yan HH; Zhang XC; Zhou Q; Su J; Wang Z; Xu CR; Huang YS; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Jiang BY; Dong S; Wu YL Lung Cancer; 2013 Jan; 79(1):33-9. PubMed ID: 23079155 [TBL] [Abstract][Full Text] [Related]
37. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? Rossi A; Pasquale R; Esposito C; Normanno N Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519 [TBL] [Abstract][Full Text] [Related]
38. Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. Wong AS; Soong R; Seah SB; Lim SW; Chuah KL; Nga ME; Chin TM; Soo RA J Thorac Oncol; 2008 Apr; 3(4):400-4. PubMed ID: 18379359 [TBL] [Abstract][Full Text] [Related]
39. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Wang S; Han X; Hu X; Wang X; Zhao L; Tang L; Feng Y; Wu D; Sun Y; Shi Y Clin Chim Acta; 2014 Mar; 430():63-70. PubMed ID: 24378285 [TBL] [Abstract][Full Text] [Related]
40. Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. Vollebergh MA; Kappers I; Klomp HM; Buning-Kager JC; Korse CM; Hauptmann M; de Visser KE; van den Heuvel MM; Linn SC J Thorac Oncol; 2010 Dec; 5(12):1939-48. PubMed ID: 21102259 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]